company background image
6185 logo

CanSino Biologics SEHK:6185 Stock Report

Last Price

HK$29.25

Market Cap

HK$11.1b

7D

14.5%

1Y

15.6%

Updated

30 Oct, 2024

Data

Company Financials +

6185 Stock Overview

Develops, manufactures, and commercializes vaccines in the People’s Republic of China.

6185 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

CanSino Biologics Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CanSino Biologics
Historical stock prices
Current Share PriceHK$29.25
52 Week HighHK$34.35
52 Week LowHK$14.80
Beta0.52
11 Month Change2.63%
3 Month Change55.75%
1 Year Change15.61%
33 Year Change-85.42%
5 Year Change-25.76%
Change since IPO-15.71%

Recent News & Updates

Recent updates

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

Jun 20
Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically

Apr 07
The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically

Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?

Feb 06
Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Oct 13
CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be

Sep 07
Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

May 12
CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Does CanSino Biologics (HKG:6185) Have A Healthy Balance Sheet?

Jan 09
Does CanSino Biologics (HKG:6185) Have A Healthy Balance Sheet?

CanSino Biologics Inc.'s (HKG:6185) Share Price Not Quite Adding Up

Sep 16
CanSino Biologics Inc.'s (HKG:6185) Share Price Not Quite Adding Up

Things Look Grim For CanSino Biologics Inc. (HKG:6185) After Today's Downgrade

Aug 31
Things Look Grim For CanSino Biologics Inc. (HKG:6185) After Today's Downgrade

Should You Be Adding CanSino Biologics (HKG:6185) To Your Watchlist Today?

Aug 29
Should You Be Adding CanSino Biologics (HKG:6185) To Your Watchlist Today?

Analysts Just Made A Major Revision To Their CanSino Biologics Inc. (HKG:6185) Revenue Forecasts

Jul 13
Analysts Just Made A Major Revision To Their CanSino Biologics Inc. (HKG:6185) Revenue Forecasts

Is CanSino Biologics (HKG:6185) Using Too Much Debt?

Jul 01
Is CanSino Biologics (HKG:6185) Using Too Much Debt?

We Think CanSino Biologics (HKG:6185) Can Stay On Top Of Its Debt

Mar 15
We Think CanSino Biologics (HKG:6185) Can Stay On Top Of Its Debt

CanSino Biologics Inc. (HKG:6185) Analysts Just Slashed Next Year's Revenue Estimates By 15%

Jan 11
CanSino Biologics Inc. (HKG:6185) Analysts Just Slashed Next Year's Revenue Estimates By 15%

Shareholder Returns

6185HK BiotechsHK Market
7D14.5%-4.4%-0.3%
1Y15.6%-13.3%18.4%

Return vs Industry: 6185 exceeded the Hong Kong Biotechs industry which returned -13.3% over the past year.

Return vs Market: 6185 underperformed the Hong Kong Market which returned 18.4% over the past year.

Price Volatility

Is 6185's price volatile compared to industry and market?
6185 volatility
6185 Average Weekly Movement11.4%
Biotechs Industry Average Movement10.4%
Market Average Movement8.9%
10% most volatile stocks in HK Market18.9%
10% least volatile stocks in HK Market4.3%

Stable Share Price: 6185 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 6185's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20091,149Xuefeng Yuwww.cansinotech.com

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination.

CanSino Biologics Inc. Fundamentals Summary

How do CanSino Biologics's earnings and revenue compare to its market cap?
6185 fundamental statistics
Market capHK$11.09b
Earnings (TTM)-HK$785.70m
Revenue (TTM)HK$816.70m

8.8x

P/S Ratio

-9.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6185 income statement (TTM)
RevenueCN¥748.53m
Cost of RevenueCN¥774.40m
Gross Profit-CN¥25.87m
Other ExpensesCN¥694.25m
Earnings-CN¥720.11m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.91
Gross Margin-3.46%
Net Profit Margin-96.20%
Debt/Equity Ratio41.3%

How did 6185 perform over the long term?

See historical performance and comparison